Education
About Us
Working with TipRanks
Follow Us
Turnstone Biologics Corp. (TSBX)
NASDAQ:TSBX
RESEARCH TOOLSreports
Top Page
Turnstone Biologics Corp.
(NASDAQ:TSBX)
36Underperform
Positive Factors
Financial Stability
The company guides to a cash runway into the second quarter of 2026, providing a degree of financial stability.
Pre-clinical Developments
The company’s pre-clinical, next-generation TIL program, TIDAL-02, could deliver value to whomever picks up Turnstone’s mantle.
Research Advancements
The evidence that selecting a specific 12-genome signature meaningfully increases TIL yield and potency is encouraging for Turnstone Biologics.
Negative Factors
Clinical Program Discontinuation
Turnstone Biologics announced the discontinuation of their lead (and sole) clinical program, TIDAL-01.
Financial Evaluation
With the removal of TIDAL-01 from estimates, the price target has been reduced to $1 from $3 and the MP rating is reiterated.
Workforce and Operations
A workforce reduction by 60% was recently implemented, indicating potential challenges within the company.
Turnstone Biologics Corp. (TSBX) vs. S&P 500 (SPY)
Market Cap
$9.48M
Dividend YieldN/A
Average Volume (3M)178.55K
Price to Earnings (P/E)―
Beta (1Y)2.90
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees80
SectorHealthcare
Sector Strength76
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.25
Shares Outstanding23,128,454
10 Day Avg. Volume148,304
30 Day Avg. Volume178,546
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)70.22
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.70Price Target Upside70.73% Upside
Rating ConsensusHold
Number of Analyst Covering2
Turnstone Biologics Corp. Business Overview & Revenue Model
Company DescriptionTurnstone Biologics Corp. (TSBX) is a biotechnology company focused on developing novel cancer immunotherapies. The company specializes in the research and development of viral immunotherapy platforms and tumor-infiltrating lymphocyte (TIL) therapies to treat various cancer types. Turnstone Biologics aims to harness the body's immune system to effectively target and eradicate cancer cells, leveraging cutting-edge scientific advancements in oncology.
How the Company Makes MoneyTurnstone Biologics Corp. generates revenue primarily through the development and commercialization of its immunotherapy products. The company's key revenue streams include licensing agreements, research collaborations, and partnerships with pharmaceutical companies. Turnstone may receive upfront payments, milestone payments, and royalties from these collaborations and licensing deals. Additionally, the company might secure funding through government grants and private investments to support its research and development activities. The successful commercialization of its proprietary therapies, once approved, would also contribute significantly to the company's earnings.
Turnstone Biologics Corp. Financial Statement Overview
Summary
Turnstone Biologics Corp. faces significant financial challenges, including declining revenues, negative profitability, and poor cash flow performance. While the balance sheet shows some improvement in equity, the overall financial health is weak, requiring urgent action to stabilize revenue and cash flow.Income Statement
Turnstone Biologics Corp. has experienced a significant decline in revenue from 2022 to 2023, followed by zero revenue in TTM. This drastic fall impacts all profitability margins, with negative gross profit and net income margins. Revenue growth is non-existent in TTM, highlighting a concerning trend for the company's income generation ability.25
Negative
Balance Sheet
The company shows a solid equity position with a positive stockholders' equity in TTM after a period of negative equity. However, the high volatility in equity and liabilities suggests financial instability. The debt-to-equity ratio is low, indicating minimal leverage risk. Overall, the balance sheet reflects moderate improvement but still shows potential risks.40
Negative
Cash Flow
Turnstone's cash flow situation shows a negative trend with declining free cash flow and operating cash flow over the periods. The company struggles to generate positive cash flows, reflecting financial stress. The ratios between cash flows and net income are unfavorable, indicating cash management issues.30
Negative
| Breakdown | |||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|
| Income Statement | Total Revenue | ||
| 0.00 | 19.31M | 73.30M | 101.29M |
| Gross Profit | |||
| -1.67M | 16.51M | 71.10M | 99.28M |
| EBIT | |||
| -78.97M | -59.03M | -31.63M | 32.99M |
| EBITDA | |||
| -77.80M | -56.23M | -28.49M | 35.71M |
| Net Income Common Stockholders | |||
| -74.42M | -55.20M | -30.83M | 33.27M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
| 82.06M | 94.78M | 82.06M | 161.02M |
| Total Assets | |||
| 114.94M | 112.81M | 114.94M | 187.24M |
| Total Debt | |||
| 5.17M | 3.21M | 5.17M | 2.68M |
| Net Debt | |||
| -29.57M | -14.58M | -29.57M | -120.70M |
| Total Liabilities | |||
| 216.41M | 14.15M | 216.41M | 269.10M |
| Stockholders Equity | |||
| -101.47M | 98.67M | -101.47M | -81.85M |
| Cash Flow | Free Cash Flow | ||
| -66.71M | -67.40M | -76.23M | -49.03M |
| Operating Cash Flow | |||
| -66.47M | -66.15M | -71.06M | -45.63M |
| Investing Cash Flow | |||
| 51.98M | -28.09M | -14.93M | -3.35M |
| Financing Cash Flow | |||
| -250.00K | 77.05M | -2.66M | 79.95M |
Turnstone Biologics Corp. Technical Analysis
Neutral
0.41
Price Trends
0.42
Negative
0.46
Negative
1.02
Negative
Market Momentum
>-0.01
Negative
53.92
Neutral
83.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSBX, the sentiment is Neutral. The current price of 0.41 is above the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.42, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.92 is Neutral, neither overbought nor oversold. The STOCH value of 83.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSBX.
Turnstone Biologics Corp. Risk Analysis
Turnstone Biologics Corp. disclosed 84 risk factors in its most recent earnings report. Turnstone Biologics Corp. reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Turnstone Biologics Corp. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.92B | 0.65 | -53.47% | 2.48% | 22.66% | 1.33% | |
48 Neutral | $42.30M | 106.65 | 24.44% | ― | 43.62% | ― | |
45 Neutral | $633.12M | ― | -42.91% | ― | ― | 2.90% | |
44 Neutral | $74.41M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $104.73M | ― | -54.21% | ― | -78.55% | -0.92% | |
41 Neutral | $351.97M | ― | -55.13% | ― | -86.25% | 36.10% | |
36 Underperform | $9.48M | ― | -94.47% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
TSBX
Turnstone Biologics Corp.
0.41
-2.53
-86.05%
FATE
Fate Therapeutics
0.91
-5.96
-86.75%
ADAP
Adaptimmune Therapeutics
0.29
-1.15
-79.86%
KURA
Kura Oncology
7.84
-13.15
-62.65%
ALLO
Allogene Therapeutics
1.62
-2.67
-62.24%
DTIL
Precision BioSciences
5.45
-6.35
-53.81%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.